SAN FRANCISCO (Thomson Financial) - The Food and Drug Administration has
approved Abbott Laboratories's Xience V drug-coated stent for coronary disease,
the Abbott Park, Ill.-based health-care company said late Wednesday.
The stent will be launched in the United States immediately, Abbott said.
Abbott shares closed the regular session up 7 cents at $54.28.
Brigid Gaffikin
bg/kh
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|